ANXA2 and chronic obstructive pulmonary disease: Farlow et al. [42] identified a 6-autoantibody panel consisting of IMPDH, phosphoglycerate mutase, ubiquillin, annexin I, annexin II, and HSP70-9B that can detect NSCLC among several patient cohorts including benign lung diseases (chronic obstructive pulmonary disease [COPD]/asthma) and benign pulmonary nodules.